Last reviewed · How we verify
NCT05556941
Metacognitive Intervention for Individuals With Severe Mental Disorders
NA trial testing Metacognitive Group Intervention in Schizophrenia in 84 participants. Completed in 30 April 2016.
30 April 2016
Quick facts
| Lead sponsor | University of Haifa |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 84 |
| Start date | 1 October 2015 |
| Primary completion | 30 April 2016 |
| Estimated completion | 30 April 2016 |
Drugs / interventions tested
- Metacognitive Group Intervention
- Occupational therapy standard care
Conditions studied
- Schizophrenia — all drugs for Schizophrenia →
Sponsor
University of Haifa
Who can join
Adults 23 to 68, any sex, with Schizophrenia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The overall aim of this study was to develop a meta-cognitive group intervention in order to apply it and to understand and distinguish the components that influence participation among people with schizophrenia
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Do symptoms moderate the association between participation and executive functions outcomes among people with schizophrenia?
Kaizerman-Dinerman A, Roe D, Demeter N, Josman N. · · 2023 · cited 4× · PMID 36650458 · DOI 10.1186/s12888-022-04510-0
Verify or expand the search:
- PubMed search for NCT05556941
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Schizophrenia
Currently open trials in the same condition.
- NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
- NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
- NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
- NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
- NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting
Other University of Haifa trials
Trials by the same sponsor.
- NCT07379801 — The Musculoskeletal System During Puberty in Dancers With Scoliosis, and the Effect of an Exercise Program · NA · recruiting
- NCT07325929 — Online Radical Acceptance Intervention for Social Anxiety Disorder · NA · not yet recruiting
- NCT06749392 — An Individual-specific Synchrony Signature · NA · recruiting
- NCT07367763 — The Relationship Between Self-Awareness and Risk of Falls During Walking in Adults · active not recruiting
- NCT06932679 — Perception of Affordances and Obstacle Crossing in People With Parkinson's Disease and Healthy Adults · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05556941 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Haifa
- Last refreshed: 3 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05556941.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing